Biogen Advances Controversial Alzheimer’s Drug to Phase 3 Despite Mixed Trial Results

Biogen has announced the progression of its experimental tau-targeted Alzheimer’s drug, gosuranemab, into Phase 3 clinical trials, despite ambiguous results from a mid-stage study. The move highlights both the pharmaceutical giant’s confidence in the therapy’s potential and the persistent challenges in developing effective treatments for Alzheimer’s disease.

Why This Is Escalating

The decision to advance gosuranemab comes amid growing scrutiny of Alzheimer’s drug development, particularly therapies targeting tau protein—a hallmark of the disease. While amyloid-beta plaques have long dominated research, tau tangles are increasingly recognized as a critical driver of neurodegeneration. Biogen’s earlier success with aducanumab, an amyloid-targeting therapy, was marred by controversy over its efficacy and approval, leaving the field hungry for clearer breakthroughs.

The Phase 2 trial of gosuranemab, known as the TANGO study, enrolled 577 patients with early Alzheimer’s. While the drug demonstrated a statistically significant reduction in tau accumulation in certain brain regions, it failed to meet its primary endpoint of slowing cognitive decline. Secondary measures, however, showed modest benefits in some patients, prompting Biogen to proceed with larger trials.

Understanding the Condition

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by:

• Memory loss and cognitive decline
• Accumulation of amyloid-beta plaques and tau tangles in the brain
• Neuroinflammation and synaptic dysfunction
• Gradual loss of independence and daily functioning

Tau proteins, which stabilize microtubules in healthy neurons, become hyperphosphorylated in Alzheimer’s, forming toxic tangles that disrupt cellular function. Unlike amyloid plaques, tau pathology correlates more closely with cognitive symptoms, making it a compelling but elusive target for drug developers.

The Road Ahead

Biogen’s Phase 3 program will include two global studies, each enrolling approximately 1,600 patients with early Alzheimer’s. The trials will evaluate gosuranemab’s efficacy in slowing disease progression, with results expected in the coming years. Analysts caution that the drug’s success hinges on whether the Phase 2 signals translate into meaningful clinical benefits.

Competitors are also racing to develop tau-targeted therapies, including Roche’s semorinemab and Eli Lilly’s zagotenemab. The field remains divided over whether targeting tau alone—or in combination with amyloid—will yield the most effective treatments.

MedSense Insight

Biogen’s gamble on gosuranemab reflects the high-stakes nature of Alzheimer’s research, where even incremental progress is celebrated. The mixed Phase 2 data underscore the complexity of tau biology and the difficulty of translating biomarker changes into tangible patient outcomes. If successful, gosuranemab could redefine treatment paradigms—but failure risks further eroding confidence in tau as a viable target.

Key Takeaway

• Biogen’s gosuranemab advances to Phase 3 despite inconclusive Phase 2 results, highlighting the urgency for Alzheimer’s therapies.
• Tau-targeted drugs represent a shift from amyloid-focused research, with potential to address neurodegeneration more directly.
• The outcome of these trials could shape the future of Alzheimer’s drug development, with implications for patients and investors alike.